
Jan 16 (Reuters) - Immunitybio Inc IBRX.O:
IMMUNITYBIO ADVANCES FIRST-LINE BCG NAIVE NMIBC PROGRAM WITH ENROLLMENT EXCEEDING EXPECTATIONS AND POSITIVE INTERIM ANALYSIS FOR ANKTIVA® PLUS BCG
IMMUNITYBIO INC: EXPANDED ACCESS PROGRAM (EAP) OF RECOMBINANT BCG PROCEEDING WELL
IMMUNITYBIO : INTERIM ANALYSIS REQUESTED BY FDA DEMONSTRATED STATISTICALLY SIGNIFICANT LONGER DURATION OF COMPLETE RESPONSE WITH ANKTIVA + BCG
IMMUNITYBIO INC: ANTICIPATES SUBMITTING BLA TO U.S. FDA BY YEAR END 2026 FOR ANKTIVA PLUS BCG
IMMUNITYBIO INC - REQUESTS FDA CONSULTATION ON RECOMBINANT BCG USE